AzTrials
AzTrials

Functional DyspepsiaGHRNCT01591174

Ghrelin and Gastric Emptying in Children With Functional Dyspepsia

An observational study of Functional Dyspepsia, run by Children's Mercy Hospital Kansas City at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this research is to see if there are differences between children who have FD and children without FD in the ability of the stomach to empty food and/or in ghrelin hormone levels before and after eating. Chronic abdominal pain is the most common persistent pain condition in children and adolescents. Read more about this study

Who is it for?
Ages 8 to 17 yearsHealthy volunteers can take part
Conditions the study is for
Functional Dyspepsia
How many people
30 participants
Where
1 siteUnited States
Study dates
May 2012to 22 Apr 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 17 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: All FD patients will be recruited from the Section of Gastroenterology at the Children's Mercy Hospital and Clinics. The control group will be recruited by advertisement within Children's Mercy Hospital.

Who may be able to join

  • All: Participants 8-17 years of age
  • FD arms: Patients identified in CMH/Abdominal Pain Team Clinic with Functional Dyspepsia who meet exclusion criteria.
  • Control arm: healthy participants who meet exclusion criteria.

Who cannot join

  • History of upper gastrointestinal surgery or intestinal obstruction.
  • History of disease or symptoms suggestive of underlying malabsorption, Inflammatory Bowel Disease (IBD), or Peptic Ulcer Disease (PUD).
  • History or evidence of chronic illness requiring regular medical care such as diabetes mellitis (DM), liver, heart, kidney, endocrine, or pulmonary disease and asthma that precludes accurate exhalation into the study breath collection apparatus.
  • Any patient with body Mass index (BMI) less than or equal to 10th percentile for age; or equal to or greater than 90th percentile for age.
  • Patient and/or parent not able to read English.
  • Current pregnancy.
Show all 10Show fewer
  • History of milk allergy.
  • Prokinetic or psychotropic medications used within the last 72 hour prior to study.
  • Inability to exhale into study breath collection apparatus as directed.
  • Recent acute illness that occurs prior to study visit.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Children's Mercy Hospital

    Kansas City, Missouri, 64108

Other trials in United States

About this study

Official title: Evaluation of Liquid Gastric Emptying and Plasma Ghrelin in Children With Functional Dyspepsia

The purpose of this research is to see if there are differences between children who have FD and children without FD in the ability of the stomach to empty food and/or in ghrelin hormone levels before and after eating.

Chronic abdominal pain is the most common persistent pain condition in children and adolescents. One of the most often diagnosed types of abdominal pain is functional dyspepsia (FD). FD is abdominal pain or discomfort (e.g., nausea, bloating) in the upper abdomen that does not get better by having a bowel movement.

Read more

One possible explanation for having FD is a delay in the emptying of food from the stomach, or delayed gastric (stomach) emptying. Failing to empty the stomach quickly enough may result in the feeling of being full and cause symptoms of bloating, nausea, vomiting and pain. Further, hormonal changes occur before, during, or after eating food that appear to impact stomach emptying.

One of the hormones that changes with meals is called ghrelin. The relationship between ghrelin and stomach emptying needs to be explored more in children with FD. Better understanding of what causes FD symptoms may help us to improve treatment for this condition.

Read the detailed description

Functional Dyspepsia (FD) is defined as the presence of persistent or recurrent pain or discomfort centered in the upper abdomen with no evidence of organic disease likely to explain the symptoms.

This pain or discomfort must not be exclusively relieved by defecation or associated with the onset of a change in stool frequency or stool form.

Initially, the FD classification criteria included 3 subtypes: ulcer-like, in which pain is the predominant symptom; dysmotility-like, in which discomfort is the predominant symptom; and, unspecified. In 2006, however, the criteria were revised by the Rome III committees. In adults, the previous FD subtypes were eliminated and replaced by two new subtypes: (i) postprandial distress syndrome (PDS), characterized by postprandial fullness or early satiety; and, (ii) epigastric pain syndrome (EPS), characterized by epigastric pain or burning unrelated to meals. In children, the Rome II subtypes were eliminated completely. Although the Rome III subtypes have only been applied within adult criteria, there also appear to be meaningful associations in children with FD which may support their adoption in later revisions of the criteria. Specifically, both inflammation (reflected by mast cell density) and self reported anxiety and depression appear to be uniquely associated with PDS in children.

FD is a common disorder of the upper gastrointestinal (GI) tract, occurring in 26% to 34% of the general population. FD is present in as many as 80% of children being evaluated for chronic abdominal pain. FD is best explained by a biopsychological model with dysfunction within the brain-gut axis. The model suggests that FD is as a result of interaction between biological (e.g., inflammation, mechanical, or sensory dysfunction), psychological (e.g., anxiety, depression, somatization), and social (e.g., interactions with parents, teachers, or peers) factors, which may be interactive with each other. Delayed gastric emptying is one of the mechanical factors which have been implicated. Other mechanisms are visceral hypersensitivity and impaired gastric fundic accommodation.

Delayed gastric emptying has been shown in up to 66% of children with FD. Most of previous studies in children used solid GE as a measure to explain the function of pyloric emptying. However, liquids GE is a good measure to predict the function of fundic accommodation, visceral hypersensitivity as well as pyloric emptying, in which, all these mechanisms were suggested in the mechanical pathophysiological model of FD specifically PDS subtypes. In order to measure gastric emptying (GE), the 13C-acetate breath test (ABT) has the potential to replace 99mtechnetium colloid-based scintigraphy which is the "gold standard" for measuring GE. ABT has an advantage over scintigraphy in that it is a rapid, technically simple, safe and inexpensive means to assess liquid GE in children. As such, it may be more easily utilized as a diagnostic technique in standard clinical practice.

Gastric motility is mainly regulated by extrinsic autonomic nerves, intrinsic neurons of the stomach, and GI hormones. It is hypothesized that these hormones strongly affect hunger and energy expenditure and may be are altered in dyspeptic disorders affecting gastric motility. Because altered gut-brain interactions may underlie symptom generation in FD and ghrelin is an important gut peptide related to the gut-brain axis, plasma concentrations of ghrelin in patients with FD have been investigated in several studies.

Ghrelin is a motilin-related peptide mainly synthesized and released by A-like cells in the stomach. Ghrelin acts as an endogenous ligand of growth hormone secretagogue receptor (GHSR). Ghrelin receptors are present in the anterior pituitary hypothalamus. There are two forms of ghrelin. The first form is acyl ghrelin, comprising 28 amino acid residues with an n-octanoyl ester at Ser3 that is essential for its biologic activity, which acts as an endogenous ligand of growth hormone secretagogue receptor type 1a (GHS-R1a). Acyl ghrelin is easily and rapidly degraded to the second form, desacyl ghrelin, or smaller fragments.

Functionally, ghrelin level progressively rises during fasting to peak just prior to a meal and fall to its lowest level about an hour after eating. Ghrelin level again starts increasing approximately 2 hours after eating to peak again before the next meal. A close relationship has been documented between ghrelin and gastric motility in rats. In humans, it has been demonstrated that ghrelin increases the gastric emptying rate in healthy, but not in obese, controls. Ghrelin has a well-established role in increasing appetite and food intake. These pieces of evidence have led to speculation that altered ghrelin function may contribute to the disturbed gastric motility and appetite loss seen in FD. Moreover, ghrelin agonist administration is found to have stimulatory effect on appetite in FD patients and idiopathic gastroparesis.

Considering that most symptoms of FD are typically related to food intake, postprandial ghrelin level has been investigated in several studies. It has been shown that fasting ghrelin level, in general, is inversely related to gastric emptying time (i,e., lower fasting ghrelin is associated with greater delay in GE). However, this relation is disrupted in FD patients, as these patients do not demonstrate an increase in fasting ghrelin level. Although results have been somewhat conflicting, some previous studies support a role for ghrelin in FD in adults. Takamori et al. reported that fasting desacyl and total ghrelin levels were significantly lower in FD patients than in controls. Further, fasting and postprandial levels were not significantly different in FD, as compared to a significant drop from fasting to postprandial level seen in controls, which suggests that fasting ghrelin does not increase as expected during fasting in FD patients. Consistent with this, Lee et al. showed that delayed GE has been reported in the majority of adults with FD where abnormally low total pre-prandial ghrelin levels were observed. However, the relationship between FD and ghrelin may differ by FD subtype. Shindo et al. reported that fasting acyl ghrelin levels were significantly lower in PDS adult patients than in healthy volunteers. Further, they demonstrated that Tmax value reflective of GE in PDS patients was significantly higher than in healthy volunteers, as measured using the 13-C (carbon) acetate breath test. These results suggested that acyl ghrelin is more biologically important and might play a role in the pathophysiology of the PDS subtype of FD through its effect on gastric emptying.

Collectively, previous studies suggest a relationship between plasma ghrelin concentration and FD, or FD subtype, in adults. Further, it seems likely that this occurs through the impact of ghrelin on gastric emptying in adults. However, to the best of our knowledge, the role of ghrelin in pediatric FD and it its relation to gastric motility in children has not been previously studied. There is a need to investigate the possible role of ghrelin in its two different forms, as well as its relation to gastric motility, in children with FD as a group and across possible subtypes in order to establish better understanding of the pathophysiology of FD. This study may help to build a mechanical pathway model for FD etiology, explore the pharmacokinetics of the ghrelin hormone, and establish its correlation to liquid gastric emptying. If a relationship is established, future work can explore a potential therapeutic role for ghrelin agonist in FD or specific FD subtypes.

Keywords
Functional Dyspepsia, Postprandial Distress Syndrome, ghrelin, C-13 acetate

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01591174
Study groupRoleWhat they receive
Functional Dyspepsia with PDSStudy participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
Functional Dyspepsia without PDSStudy participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
Control GroupHealthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Children with FD: exploration of relationships between ghrelin concentration, liquid gastric emptying, and dyspepsia subtype

    Blood samples will be compared pre/post test meal for FD cohorts (EPS/PDS), controls: 0 time/baseline; 6 times/post meal. Associations between relationship of plasma ghrelin type's (acyl and desacyl) pre and postprandial levels \& gastric emptying studied.C-13 acetate to be given and amount of 13CO2 determined for each time point (1 pre/ 14 post meal) using equation nested in software package with UBit IR-300 spectrometer. The concentration of 13CO2 and 12CO2 in the exhaled breath samples to be measured by infrared spectrometry.

    Measured: Duration of 4-hour study visit

Secondary outcomes (1)
  1. Children with FD: SUBJECTIVE SYMPTOM SEVERITY and correlations between plasma ghrelin concentrations (acyl and desacyl) and gastric emptying.

    Intensity of 5 symptoms associated with FD (burning, nausea, bloating, belching, epigastric pain) will be graded x6 (1 pre and 5 post-meal).

    Measured: Duration of 4-hour study visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 May 2012 (estimated)
  2. Study startMay 2012
  3. Primary completion22 Apr 2016
  4. Study completion22 Apr 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01591174
Sponsor's protocol ID
Ghrelin 12010078
Acronym
GHR
Status last verified
May 2019
First submitted
2 May 2012
Last updated
20 May 2019
Results posted
No
Data monitoring committee
No

Publications

  • Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90. doi: 10.1053/j.gastro.2006.03.008. No abstract available.

    PubMed 16678553
  • Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol. 2006 Jun;41(6):513-23. doi: 10.1007/s00535-006-1847-5.

    PubMed 16868798
  • Akamizu T, Iwakura H, Ariyasu H, Kangawa K. Ghrelin and functional dyspepsia. Int J Pept. 2010;2010:548457. doi: 10.1155/2010/548457. Epub 2010 Jan 12.

    PubMed 20721353
  • Schurman JV, Singh M, Singh V, Neilan N, Friesen CA. Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):298-303. doi: 10.1097/MPG.0b013e3181d1363c.

    PubMed 20479684
  • Castillo EJ, Camilleri M, Locke GR, Burton DD, Stephens DA, Geno DM, Zinsmeister AR. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol. 2004 Nov;2(11):985-96. doi: 10.1016/s1542-3565(04)00454-9.

    PubMed 15551251
  • Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993 Sep;38(9):1569-80. doi: 10.1007/BF01303162.

    PubMed 8359066
  • Schurman JV, Friesen CA, Danda CE, Andre L, Welchert E, Lavenbarg T, Cocjin JT, Hyman PE. Diagnosing functional abdominal pain with the Rome II criteria: parent, child, and clinician agreement. J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):291-5. doi: 10.1097/01.mpg.0000178438.64675.c4.

    PubMed 16131983
  • Hyams JS, Hyman PE. Recurrent abdominal pain and the biopsychosocial model of medical practice. J Pediatr. 1998 Oct;133(4):473-8. doi: 10.1016/s0022-3476(98)70053-8. No abstract available.

    PubMed 9787683
  • Takamori K, Mizuta Y, Takeshima F, Akazawa Y, Isomoto H, Ohnita K, Ohba K, Omagari K, Shikuwa S, Kohno S. Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J Clin Gastroenterol. 2007 May-Jun;41(5):477-83. doi: 10.1097/01.mcg.0000225614.94470.47.

    PubMed 17450030
  • Ogiso K, Asakawa A, Amitani H, Inui A. Ghrelin: a gut hormonal basis of motility regulation and functional dyspepsia. J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:67-72. doi: 10.1111/j.1440-1746.2011.06630.x.

    PubMed 21443713
  • Riezzo G, Chiloiro M, Guerra V, Borrelli O, Salvia G, Cucchiara S. Comparison of gastric electrical activity and gastric emptying in healthy and dyspeptic children. Dig Dis Sci. 2000 Mar;45(3):517-24. doi: 10.1023/a:1005493123557.

    PubMed 10749327
  • Heyman S. Gastric emptying in children. J Nucl Med. 1998 May;39(5):865-9.

    PubMed 9591590
  • Hou XH, Li Q, Zhu L, Xie X, Chen JD. Correlation of gastric liquid emptying with various thresholds of sensation in healthy controls and patients with functional dyspepsia. Dig Dis Sci. 2004 Feb;49(2):188-95. doi: 10.1023/b:ddas.0000017437.20932.8b.

    PubMed 15104356
  • Maes BD, Ghoos YF, Geypens BJ, Hiele MI, Rutgeerts PJ. Relation between gastric emptying rate and energy intake in children compared with adults. Gut. 1995 Feb;36(2):183-8. doi: 10.1136/gut.36.2.183.

    PubMed 7883214
  • Jones BL, Pearce RE, Abdel-Rahman SM, Friesen CA, James LP, Kearns GL. Characterization of delayed liquid gastric emptying in children by the (13)C-acetate breath test. J Breath Res. 2009 Dec;3(4):047004. doi: 10.1088/1752-7155/3/4/047004. Epub 2009 Nov 27.

    PubMed 21386201

Questions about this trial

What is this clinical trial studying?

An observational study of Functional Dyspepsia, run by Children's Mercy Hospital Kansas City at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Children with FD: exploration of relationships between ghrelin concentration, liquid gastric emptying, and dyspepsia subtype (time frame: Duration of 4-hour study visit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01591174, which also lists 35 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in